PIC/S PE 009-18 Part I 制剂GMP第1–3章(质量体系·人员·厂房设备)中英双语译述
PE 009-18 Part I 制剂 GMP(第1–3章:质量体系·人员·厂房设备)中英双语
PIC/S PE 009-18 Part I 第1–3章中英双语译述发布,覆盖药品质量体系、人员与厂房设备三章必查内容。第1章要求生产许可持有人建立全面设计并正确实施的药品质量体系,纳入GMP与质量风险管理,体系有效性通常在场所层面体现。译文按中文在上、英文可回查排布,冲突时以英文原版为准。
PIC/S PE 009-18 · Part I · Good Manufacturing Practice (Medicinal Products)
——本文译述自 PIC/S PE 009-18《Guide to Good Manufacturing Practice for Medicinal Products》(© PIC/S 2026)。中文为学习性译文,原文与译文冲突时以英文原版为准。
PIC/S Secretariat · www.picscheme.org
PE 009-18 Part I 制剂 GMP(第1–3章:质量体系·人员·厂房设备)中英双语
从质量体系到人员与厂房设备,建立一套能经受检查的设计逻辑
Part I 是 PE 009-18 的主体,管的是「制剂怎么造才合规」。前面我们讲了总纲和引言,这一篇进入真正的硬核:质量体系、人员、厂房设备——这三章是每一次 GMP 检查的必查项,也是企业最容易栽跟头的地方。我们按「中文在上、英文可回查」排布,手机上读中文不费劲,要抠原文往下翻即可。
图示:英文原文 + 中文译文,逐段对照
第1章 药品质量体系
Chapter 1 Pharmaceutical Quality System
原则 生产许可持有人必须生产药品,以确保其适合预期用途,符合上市许可或临床试验许可(视情况而定)的要求,并且不会因安全性、质量或疗效不足而使患者面临风险。实现这一质量目标是高级管理层的责任,需要公司内许多不同部门和各级员工的参与和承诺,以及公司供应商和分销商的参与和承诺。为了可靠地实现这一质量目标,必须建立全面设计且正确实施的药品质量体系(PQS),该体系应包含药品生产质量管理规范(GMP)和质量风险管理。该体系应完整成文并对其有效性进行监测。药品质量体系的所有部分均应配备足够的合格人员,以及适宜且充分的厂房、设备和设施。生产许可持有人和授权人还有额外的法律责任。 质量管理、药品生产质量管理规范(GMP)和质量风险管理这三个基本概念相互关联。在此对其进行阐述,旨在强调它们之间的关系及其对药品生产和控制的根本重要性。 药品质量体系 1 1.1 质量管理是一个广泛的概念,涵盖所有单独或共同影响产品质量的事项。它是为确保药品达到其预期用途所需质量而作出的有组织的安排的总和。因此,质量管理包含药品生产质量管理规范(GMP)。 1.2 GMP适用于从临床试验药品生产、技术转移、商业化生产直至产品停产的生命周期阶段。然而,药品质量体系可延伸至ICH Q10中所述的药品开发生命周期阶段,尽管该阶段是可选的,但应促进创新和持续改进,并加强药品开发活动与生产活动之间的联系。
PRINCIPLE The holder of a Manufacturing Authorisation must manufacture medicinal products so as to ensure that they are fit for their intended use, comply with the requirements of the Marketing Authorisation or Clinical Trial Authorisation, as appropriate, and do not place patients at risk due to inadequate safety, quality or efficacy. The attainment of this quality objective is the responsibility of senior management and requires the participation and commitment by staff in many different departments and at all levels within the company, by the company’s suppliers and by its distributors. To achieve this quality objective reliably there must be a comprehensively designed and correctly implemented Pharmaceutical Quality System incorporating Good Manufacturing Practice and Quality Risk Management. It should be fully documented and its effectiveness monitored. All parts of the Pharmaceutical Quality System should be adequately resourced with competent personnel, and suitable and sufficient premises, equipment and facilities. There are additional legal responsibilities for the holder of the Manufacturing Authorisation and for the Authorised Person(s). The basic concepts of Quality Management, Good Manufacturing Practice (GMP) and Quality Risk Management are inter-related. They are described here in order to emphasise their relationships and their fundamental importance to the production and control of medicinal products. PHARMACEUTICAL QUALITY SYSTEM 1 1.1 Quality Management is a wide-ranging concept, which covers all matters, which individually or collectively influence the quality of a product. It is the sum total of the organised arrangements made with the objective of ensuring that medicinal products are of the quality required for their intended use. Quality Management therefore incorporates Good Manufacturing Practice. 1.2 GMP applies to the lifecycle stages from the manufacture of investigational medicinal products, technology transfer, commercial manufacturing through to product discontinuation. However the Pharmaceutical Quality System can extend to the pharmaceutical development lifecycle stage as described in ICH Q10, which while optional, should facilitate innovation and continual improvement and strengthen the link between pharmaceutical development and manufacturing activities.
1 国家要求制造商建立并实施有效的药品质量保证体系。本章使用“药品质量体系”这一术语,是为了与ICH Q10的术语保持一致。就本章而言,这些术语可视为可互换。
1 National requirements require manufacturers to establish and implement an effective pharmaceutical quality assurance system. The term Pharmaceutical Quality System is used in this chapter in the interests of consistency with ICH Q10 terminology. For the purposes of this chapter these terms can be considered interchangeable.
1.3 在开发新的药品质量体系或修改现有体系时,应考虑到公司活动的规模和复杂性。体系的设计应包含适当的风险管理原则,包括使用适当的工具。虽然体系的某些方面可以是全公司范围的,其他方面可以是特定于场所的,但体系的有效性通常在场所层面得以体现。 1.4 适用于药品生产的药品质量体系应确保:
1.3 The size and complexity of the company’s activities should be taken into consideration when developing a new Pharmaceutical Quality System or modifying an existing one. The design of the system should incorporate appropriate risk management principles including the use of appropriate tools. While some aspects of the system can be company-wide and others site-specific, the effectiveness of the system is normally demonstrated at the site level. 1.4 A Pharmaceutical Quality System appropriate for the manufacture of medicinal products should ensure that:
(i)通过设计、策划、实施、维护并持续改进一个能够持续交付具有适当质量属性产品的体系,实现产品实现;
(i) Product realisation is achieved by designing, planning, implementing, maintaining and continuously improving a system that allows the consistent delivery of products with appropriate quality attributes;
(ii)在整个生命周期阶段对产品和工艺知识进行管理;
(ii) Product and process knowledge is managed throughout all lifecycle stages;
(iii)药品的设计和开发方式应考虑到
(iii) Medicinal products are designed and developed in a way that takes account
药品生产质量管理规范(GMP)的要求;
of the requirements of Good Manufacturing Practice;
(iv)生产和控制操作应有明确规定,并采用药品生产质量管理规范(GMP);
(iv) Production and control operations are clearly specified and Good Manufacturing Practice adopted;
(v)管理职责应有明确规定;
(v) Managerial responsibilities are clearly specified;
(vi)就正确起始物料和包装物料的生产、供应和使用,供应商的选择和监测,以及核实每次交付
(vi) Arrangements are made for the manufacture, supply and use of the correct
均来自经批准的供应链作出安排;
starting and packaging materials, the selection and monitoring of suppliers and for verifying that each delivery is from the approved supply chain;
(vii)建立相应流程,以确保对外包活动的管理;
(vii) Processes are in place to assure the management of outsourced activities;
(viii)通过开发并使用针对工艺性能和产品质量的有效监测系统和控制体系,
(viii) A state of control is established and maintained by developing and using
建立并维持受控状态;
effective monitoring and control systems for process performance and product quality;
(ix)在产品放行、偏差调查以及对未来潜在偏差采取预防措施时,
(ix) The results of product and processes monitoring are taken into account in
考虑产品和工艺监测的结果;
batch release, in the investigation of deviations, and, with a view to taking preventive action to avoid potential deviations occurring in the future;
(x)实施对中间产品的所有必要控制,以及任何其他过程控制和验证;
(x) All necessary controls on intermediate products, and any other in-process controls and validations are carried out;
(xi)通过实施与当前工艺和产品的知识水平相适应的质量改进,促进持续改进;
(xi) Continual improvement is facilitated through the implementation of quality improvements appropriate to the current level of process and product knowledge;
(xii)就计划变更的预先评估及其在实施前的批准作出安排,
(xii) Arrangements are in place for the prospective evaluation of planned
同时考虑到需要时须进行法规申报和批准;
changes and their approval prior to implementation taking into account regulatory notification and approval where required;
(xiii)任何变更实施后,应进行评价,以确认
(xiii) After implementation of any change, an evaluation is undertaken to confirm
质量目标已实现,且未对产品质量产生非预期的有害影响;
the quality objectives were achieved and that there was no unintended deleterious impact on product quality;
(xiv)在偏差、可疑产品缺陷及其他问题的调查中,
(xiv) An appropriate level of root cause analysis should be applied during the
应运用适当程度的根本原因分析;
investigation of deviations, suspected product defects and other problems.
这可使用质量风险管理原则来确定。在无法确定该问题真实根本原因的情况下,应考虑识别最可能的根本原因并予以解决。在怀疑或确认人为错误为原因时,应予以论证,并审慎确保未忽视实际存在的工艺、程序或系统性错误或问题。应针对调查确定并采取适当的纠正措施和/或预防措施(CAPA)。此类措施的有效性应根据质量风险管理原则进行监测和评估;
This can be determined using Quality Risk Management principles. In cases where the true root cause(s) of the issue cannot be determined, consideration should be given to identifying the most likely root cause(s) and to addressing those. Where human error is suspected or identified as the cause, this should be justified having taken care to ensure that process, procedural or system based errors or problems have not been overlooked, if present. Appropriate corrective actions and/or preventive actions (CAPAs) should be identified and taken in response to investigations. The effectiveness of such actions should be monitored and assessed, in line with Quality Risk Management principles;
(xv)在授权人证明每个生产批已按照上市许可
(xv) Medicinal products are not sold or supplied before an Authorised Person
以及有关药品生产、控制和放行的任何其他法规的要求生产和控制之前,不得销售或供应药品;
has certified that each production batch has been produced and controlled in accordance with the requirements of the Marketing Authorisation and any other regulations relevant to the production, control and release of medicinal products;
(xvi)存在适当的安排,以尽可能确保药品的贮存、分发及后续处理
(xvi) Satisfactory arrangements exist to ensure, as far as possible, that the
能够在其整个有效期(货架寿命)内保持质量;
medicinal products are stored, distributed and subsequently handled so that quality is maintained throughout their shelf life;
(xvii)建立自检和/或质量审计流程,定期
(xvii) There is a process for self-inspection and/or quality audit, which regularly
评价药品质量体系的有效性和适用性。 1.5 高级管理层负有最终责任,确保建立有效且资源充足的药品质量体系,并在整个组织内明确、传达和实施角色、职责和权限。高级管理层对药品质量体系的领导与积极参与至关重要。该领导力应确保组织内各级和各场所员工对药品质量体系的支持与承诺。 1.6 应在高级管理层的参与下,对药品质量体系的运行进行定期管理评审,以识别产品、工艺及体系本身的持续改进机会。 1.7 药品质量体系应予以规定并成文。应建立质量手册或同等文件,并应包含包括管理职责在内的质量管理体系的描述。
appraises the effectiveness and applicability of the Pharmaceutical Quality System. 1.5 Senior management has the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place, adequately resourced and that roles, responsibilities, and authorities are defined, communicated and implemented throughout the organisation. Senior management’s leadership and active participation in the Pharmaceutical Quality System is essential. This leadership should ensure the support and commitment of staff at all levels and sites within the organisation to the Pharmaceutical Quality System. 1.6 There should be periodic management review, with the involvement of senior management, of the operation of the Pharmaceutical Quality System to identify opportunities for continual improvement of products, processes and the system itself. 1.7 The Pharmaceutical Quality System should be defined and documented. A Quality Manual or equivalent documentation should be established and should contain a description of the quality management system including management responsibilities.
药品生产质量管理规范(GMP) 1.8 药品生产质量管理规范(GMP)是质量管理的组成部分,它确保产品持续稳定地生产和控制,达到适合其预期用途的质量标准,并符合上市许可、临床试验许可或产品规格的要求。药品生产质量管理规范(GMP)涉及生产和质量控制两方面。GMP的基本要求是:
GOOD MANUFACTURING PRACTICE FOR MEDICINAL PRODUCTS 1.8 Good Manufacturing Practice is that part of Quality Management which ensures that products are consistently produced and controlled to the quality standards appropriate to their intended use and as required by the Marketing Authorisation, Clinical Trial Authorisation or product specification. Good Manufacturing Practice is concerned with both production and quality control. The basic requirements of GMP are that:
(i)所有生产工艺均有明确定义,根据经验进行系统性审核,并证明能够持续生产符合要求和规格的药品;
(i) All manufacturing processes are clearly defined, systematically reviewed in the light of experience and shown to be capable of consistently manufacturing medicinal products of the required quality and complying with their specifications;
(ii)生产工艺的关键步骤和工艺的重大变更均经过验证;
(ii) Critical steps of manufacturing processes and significant changes to the process are validated;
(iii)提供GMP所需的所有必要设施,包括:
(iii) All necessary facilities for GMP are provided including:
• 具备相应资质并经过培训的人员; • 适宜的厂房和空间; • 合适的设备和服务; • 正确的物料、容器和标签; • 符合药品质量体系的经批准的规程和指令; • 适宜的贮存和运输。
• Appropriately qualified and trained personnel; • Adequate premises and space; • Suitable equipment and services; • Correct materials, containers and labels; • Approved procedures and instructions, in accordance with the Pharmaceutical Quality System; • Suitable storage and transport.
(v)指令和规程以指导形式撰写,语言清晰明确,且特别适用于所提供的设施;
(iv) Instructions and procedures are written in an instructional form in clear and unambiguous language, specifically applicable to the facilities provided;
(vi)规程得到正确执行,且操作人员经过相应培训;
(v) Procedures are carried out correctly and operators are trained to do so;
(vii)在生产过程中通过手工和/或记录仪器形成记录,证明已实际执行所规定规程和指令要求的全部步骤,且产品的数量和质量符合预期;
(vi) Records are made, manually and/or by recording instruments, during manufacture which demonstrate that all the steps required by the defined procedures and instructions were in fact taken and that the quantity and quality of the product was as expected;
(viii)任何重大偏差均得到完整记录,并以为
(vii) Any significant deviations are fully recorded, investigated with the objective
确定根本原因和采取适当纠正与预防措施为目标进行调查;
of determining the root cause and appropriate corrective and preventive action implemented;
(ix)保存包括分销在内的生产记录,以可理解且可获取的形式留存,
(viii) Records of manufacture including distribution which enable the complete
使批次的完整历史可追溯;
history of a batch to be traced are retained in a comprehensible and accessible form;
(x)产品的分发将对其质量的任何风险降至最低,并
(ix) The distribution of the products minimises any risk to their quality and takes
考虑到良好分销规范;
account of good distribution practice;
(xi)应建立可从销售或供应中召回任何产品批的系统;
(x) A system is available to recall any batch of product, from sale or supply;
(xi)对产品投诉进行检查,调查质量缺陷的原因,并就缺陷产品采取适当措施并防止再发生。 质量控制 1.9 质量控制是药品生产质量管理规范(GMP)的组成部分,涉及取样、质量标准和检验,以及确保必要且相关的检验实际得以实施,并在判定质量合格之前不得放行使用物料、也不得放行销售或供应产品的组织、文件和放行程序。质量控制的基本要求是:
(xi) Complaints about products are examined, the causes of quality defects investigated and appropriate measures taken in respect of the defective products and to prevent reoccurrence. QUALITY CONTROL 1.9 Quality Control is that part of Good Manufacturing Practice which is concerned with sampling, specifications and testing, and with the organisation, documentation and release procedures which ensure that the necessary and relevant tests are actually carried out and that materials are not released for use, nor products released for sale or supply, until their quality has been judged to be satisfactory. The basic requirements of Quality Control are that:
(i)具备充分的设施、经过培训的人员和经批准的规程,用于起始物料、包装材料、中间体、散装产品和成品的取样和检验,并在适当时用于GMP目的的环境条件监测;
(i) Adequate facilities, trained personnel and approved procedures are available for sampling and testing starting materials, packaging materials, intermediate, bulk, and finished products, and where appropriate for monitoring environmental conditions for GMP purposes;
(ii)起始物料、包装材料、中间产品、散装产品和成品的样品由经批准的人员和方法抽取;
(ii) Samples of starting materials, packaging materials, intermediate products, bulk products and finished products are taken by approved personnel and methods;
(iii)检验方法经过验证;
(iii) Test methods are validated;
(iv)通过手工和/或记录仪器形成记录,证明所有必需的取样、检查和检验程序均已实际执行。任何偏差均得到完整记录并调查;
(iv) Records are made, manually and/or by recording instruments, which demonstrate that all the required sampling, inspecting and testing procedures were actually carried out. Any deviations are fully recorded and investigated;
(v)成品所含活性成分符合上市许可或临床试验许可的定性和定量组成,达到所需的纯度,并装在适当的容器中且标签正确;
(v) The finished products contain active ingredients complying with the qualitative and quantitative composition of the Marketing Authorisation or Clinical Trial Authorisation, are of the purity required, and are enclosed within their proper containers and correctly labelled;
(vi)记录检验结果,并正式评价
(vi) Records are made of the results of inspection and that testing of materials,
物料、中间体、散装产品和成品的检验是否符合质量标准。产品评价包括对相关生产文件的审查与评价,以及对偏离规定程序的偏差的评价;
intermediate, bulk, and finished products is formally assessed against specification. Product assessment includes a review and evaluation of relevant production documentation and an assessment of deviations from specified procedures;
(vii)在授权人证明产品
(vii) No batch of product is released for sale or supply prior to certification by an
符合相关许可的要求之前,任何产品批均不得放行销售或供应;
Authorised Person that it is in accordance with the requirements of the relevant authorisations;
(viii)根据附录19留存足够的起始物料和产品的对照样品,以便在必要时
(viii) Sufficient reference samples of starting materials and products are retained
对产品进行后续检验,且样品留存于最终包装中。
in accordance with Annex 19 to permit future examination of the product if necessary and that the sample is retained in the final pack.
产品质量回顾 1.10 应对所有已获授权的药品(包括仅用于出口的产品)进行定期的或滚动的质量回顾,目的是确认现有工艺的一致性、当前起始物料和成品质量标准的适宜性,突出任何趋势,并识别产品和工艺的改进。此类回顾通常应每年进行并记录,同时考虑以往的回顾,并至少应包括:
PRODUCT QUALITY REVIEW 1.10 Regular periodic or rolling quality reviews of all authorised medicinal products, including export only products, should be conducted with the objective of verifying the consistency of the existing process, the appropriateness of current specifications for both starting materials and finished product, to highlight any trends and to identify product and process improvements. Such reviews should normally be conducted and documented annually, taking into account previous reviews, and should include at least:
(i)对起始物料(包括产品中使用的包装材料)的回顾,特别是来自新来源的物料,尤其是活性物质供应链可追溯性的回顾;
(i) A review of starting materials including packaging materials used in the product, especially those from new sources and in particular the review of supply chain traceability of active substances;
(ii)对关键过程控制和成品结果的回顾;
(ii) A review of critical in-process controls and finished product results;
(iii)对所有不符合既定质量标准的批次及其调查的回顾;
(iii) A review of all batches that failed to meet established specification(s) and their investigation;
(iv)对所有重大偏差或不符合项、其相关调查以及所采取纠正与预防措施结果的有效性的回顾;
(iv) A review of all significant deviations or non-conformances, their related investigations, and the effectiveness of resultant corrective and preventive actions taken;
(v)对工艺或分析方法所有已实施变更的回顾;
(v) A review of all changes carried out to the processes or analytical methods;
(vi)对已提交、批准或拒绝的上市许可变更的回顾,包括第三国(仅出口)档案的变更;
(vi) A review of Marketing Authorisation variations submitted, granted or refused, including those for third country (export only) dossiers;
(vii)对稳定性监测计划结果及任何
(vii) A review of the results of the stability monitoring programme and any
不良趋势的回顾;
adverse trends;
(viii)对所有质量相关的退货、投诉和召回以及
(viii) A review of all quality-related returns, complaints and recalls and the
当时所进行的调查的回顾;
investigations performed at the time;
(ix)对任何先前产品、工艺或设备
(ix) A review of adequacy of any other previous product process or equipment
纠正措施充分性的回顾;
corrective actions;
(x)对于新的上市许可和上市许可的变更,回顾其上市后承诺;
(x) For new Marketing Authorisations and variations to Marketing Authorisations, a review of post-marketing commitments;
(xi)相关设备和公用系统(例如HVAC、
(xi) The qualification status of relevant equipment and utilities, e.g. HVAC,
水、压缩气体等)的确认状态;
water, compressed gases, etc;
(xii)对第7章所定义任何合同安排的回顾,以确保
(xii) A review of any contractual arrangements as defined in Chapter 7 to ensure
其最新有效。 1.11 制造商(以及在不同情况下时,上市许可持有人)应评价回顾的结果,并评估是否应在药品质量体系下采取纠正与预防措施或进行任何再验证。应建立管理规程,用于对这些措施的持续管理和回顾,并在自检中核实这些规程的有效性。质量回顾可以
that they are up to date. 1.11 The manufacturer and, where different, Marketing Authorisation holder should evaluate the results of the review and an assessment made as to whether corrective and preventive action or any revalidation should be undertaken, under the Pharmaceutical Quality System. There should be management procedures for the ongoing management and review of these actions and the effectiveness of these procedures verified during self-inspection. Quality reviews may be
在科学上合理的情况下,按产品类型(例如固体剂型、液体制剂、无菌产品等)进行分组。
grouped by product type, e.g. solid dosage forms, liquid dosage forms, sterile products, etc. where scientifically justified.
在上市许可持有人并非制造商的情况下,各相关方之间应订立技术协议,明确其在编制产品质量回顾中的各自职责。负责最终批放行的授权人应与上市许可持有人共同确保质量回顾及时且准确地进行。 质量风险管理 1.12 质量风险管理是对药品质量风险进行评估、控制、沟通与回顾的系统化过程。它既可以先验地应用,也可以回顾地应用。 1.13 质量风险管理的原则是:
Where the Marketing Authorisation holder is not the manufacturer, there should be a technical agreement in place between the various parties that defines their respective responsibilities in producing the product quality review. The Authorised Person responsible for final batch certification together with the Marketing Authorisation holder should ensure that the quality review is performed in a timely manner and is accurate. QUALITY RISK MANAGEMENT 1.12 Quality Risk Management is a systematic process for the assessment, control, communication and review of risks to the quality of the medicinal product. It can be applied both proactively and retrospectively. 1.13 The principles of Quality Risk Management are that:
(i)对质量风险的评价基于科学知识、工艺经验,并最终与保护患者相联系;
(i) The evaluation of the risk to quality is based on scientific knowledge, experience with the process and ultimately links to the protection of the patient;
(ii)质量风险管理过程的投入程度、正式程度和文件化水平应与风险水平相称。
(ii) The level of effort, formality and documentation of the Quality Risk Management process is commensurate with the level of risk.
质量风险管理过程和应用的示例,除其他外,可见附录20或ICH Q9。
Examples of the processes and applications of Quality Risk Management can be found inter alia in Annex 20 or ICHQ9.
图示:Part I / Part II / 附录,是一套环
关注后续持续更新
第2章 人员
Chapter 2 Personnel
原则
PRINCIPLE
药品的正确生产依赖于人员。因此,必须有足够数量的合格人员来执行属于制造商责任的所有任务。个人职责应被相关人员清晰理解并记录。所有人员应了解影响其工作的药品生产质量管理规范(GMP)原则,并接受与其需求相关的初始培训和持续培训,包括卫生要求。 概述 2.1 制造商应拥有足够数量具备必要资质和实际操作经验的人员。高级管理层应确定并提供充分且适宜的资源(人力、财力、物料、厂房和设备),以实施和保持药品质量体系并持续改进其有效性。任何个人的职责范围不应过于广泛而对质量造成风险。 2.2 制造商必须设有组织机构图,其中清晰显示生产负责人、质量控制负责人以及在适用时第2.5点所述的保证负责人或质量部门负责人之间的相互关系,以及授权人在管理层级中的位置。 2.3 担任负责岗位的人员应有书面岗位描述记录的特定职责,并拥有履行其职责的充分权限。其职责可委托给具有满意资质水平的指定副职。在应用药品生产质量管理规范(GMP)的相关人员中,职责之间不应存在缺口或无法解释的重叠。 2.4 高级管理层负有最终责任,确保建立有效的药品质量体系以实现质量目标,并且在整个组织内明确、传达和实施角色、职责和权限。高级管理层应确立质量方针,描述公司与质量相关的整体意图和方向,并应通过参与管理评审,确保药品质量体系和GMP符合性的持续适宜性和有效性。
The correct manufacture of medicinal products relies upon people. For this reason there must be sufficient qualified personnel to carry out all the tasks which are the responsibility of the manufacturer. Individual responsibilities should be clearly understood by the individuals and recorded. All personnel should be aware of the principles of Good Manufacturing Practice that affect them and receive initial and continuing training, including hygiene instructions, relevant to their needs. GENERAL 2.1 The manufacturer should have an adequate number of personnel with the necessary qualifications and practical experience. Senior management should determine and provide adequate and appropriate resources (human, financial, materials, facilities and equipment) to implement and maintain the Pharmaceutical Quality System and continually improve its effectiveness. The responsibilities placed on any one individual should not be so extensive as to present any risk to quality. 2.2 The manufacturer must have an organisation chart in which the relationships between the heads of Production, Quality Control and where applicable Head of Quality Assurance or Quality Unit referred to in point 2.5 and the position of the Authorised Person(s) are clearly shown in the managerial hierarchy. 2.3 People in responsible positions should have specific duties recorded in written job descriptions and adequate authority to carry out their responsibilities. Their duties may be delegated to designated deputies of a satisfactory qualification level. There should be no gaps or unexplained overlaps in the responsibilities of those personnel concerned with the application of Good Manufacturing Practice. 2.4 Senior management has the ultimate responsibility to ensure an effective Pharmaceutical Quality System is in place to achieve the quality objectives, and, that roles, responsibilities, and authorities are defined, communicated and implemented throughout the organisation. Senior management should establish a quality policy that describes the overall intentions and direction of the company related to quality and should ensure continuing suitability and effectiveness of the Pharmaceutical Quality System and GMP compliance through participation in management review.
关键人员 2.5 高级管理层应任命关键管理人员,包括生产负责人、质量控制负责人,以及如果上述人员中至少一人不负责产品放行时,为此指定的授权人。通常,关键岗位应由专职人员担任。生产负责人和质量控制负责人必须相互独立。在大型组织中,可能需要将2.7、2.8和2.9中列出的某些职能进行委托。此外,根据公司的规模和组织结构,可任命单独的保证负责人或质量部门负责人。在存在此类职能的情况下,2.7、2.8和2.9中所述的某些职责通常与质量控制负责人和生产负责人分担,因此高级管理层应审慎确保角色、职责和权限得到明确界定。 2.6 授权人的职责在国家要求中予以规定,可概括如下:
KEY PERSONNEL 2.5 Senior Management should appoint Key Management Personnel including the head of Production, the head of Quality Control, and if at least one of these persons is not responsible for the release of products the Authorised Person(s) designated for the purpose. Normally, key posts should be occupied by full-time personnel. The heads of Production and Quality Control must be independent from each other. In large organisations, it may be necessary to delegate some of the functions listed in 2.7, 2.8 and 2.9. Additionally, depending on the size and organisational structure of the company, a separate Head of Quality Assurance or Head of the Quality Unit may be appointed. Where such a function exists usually some of the responsibilities described in 2.7, 2.8 and 2.9 are shared with the Head of Quality Control and Head of Production and senior management should therefore take care that roles, responsibilities, and authorities are defined. 2.6 The duties of the Authorised Person(s) are described in the national requirements and can be summarised as follows:
a) 授权人必须确保每批药品的生产和检查均符合该国现行法律以及上市许可的要求;
a) An Authorised Person must ensure that each batch of medicinal products has been manufactured and checked in compliance with the laws in force in that country and in accordance with the requirements of the Marketing Authorisation;
b) 授权人必须满足国家立法规定的资质要求,应长期且持续地为生产许可持有人所支配,以履行其职责;
b) The Authorised Person(s) must meet the qualification requirements laid down in the national legislation, they shall be permanently and continuously at the disposal of the holder of the Manufacturing Authorisation to carry out their responsibilities;
c) 授权人的职责可以委托,但只能委托给其他授权人。 2.7 生产负责人通常具有以下职责:
c) The responsibilities of an Authorised Person may be delegated, but only to other Authorised Person(s). 2.7 The head of Production generally has the following responsibilities:
(i)确保产品按照适当的文件生产和贮存,以获得所需的质量;
(i) To ensure that products are produced and stored according to the appropriate documentation in order to obtain the required quality;
(ii)批准与生产操作相关的指令,并确保其严格实施;
(ii) To approve the instructions relating to production operations and to ensure their strict implementation;
(iii)确保生产记录得到评价并由授权人签字;
(iii) To ensure that the production records are evaluated and signed by an authorised person;
(iv)确保其部门、厂房和
(iv) To ensure the qualification and maintenance of his department, premises
设备的确认与维护;
and equipment;
(v)确保进行适当的验证;
(v) To ensure that the appropriate validations are done;
(vi)确保其部门人员所需的初始和持续培训
(vi) To ensure that the required initial and continuing training of his department
得以实施,并根据需要进行调整。
personnel is carried out and adapted according to need.
2.8 质量控制负责人通常具有以下职责:
2.8 The head of Quality Control generally has the following responsibilities:
(i)根据其判断批准或拒收起始物料、包装材料、中间体、散装产品和成品;
(i) To approve or reject, as he/she sees fit, starting materials, packaging materials, intermediate, bulk and finished products;
(ii)确保执行所有必要的检验,并对相关记录进行评价;
(ii) To ensure that all necessary testing is carried out and the associated records evaluated;
(iii)批准质量标准、取样指令、检验方法和其他
(iii) To approve specifications, sampling instructions, test methods and other
质量控制规程;
Quality Control procedures;
(iv)批准并监测任何合同分析机构;
(iv) To approve and monitor any contract analysts;
(v)确保其部门、厂房和设备的确认与维护;
(v) To ensure the qualification and maintenance of his/her department, premises and equipment;
(vi)确保进行适当的验证;
(vi) To ensure that the appropriate validations are done;
(vii)确保其部门人员所需的初始和持续培训
(vii) To ensure that the required initial and continuing training of his department
得以实施,并根据需要进行调整。
personnel is carried out and adapted according to need.
质量控制的其余职责在第6章概述。 2.9 生产负责人、质量控制负责人,以及在相关时保证负责人或质量部门负责人,通常承担一些共同的或联合行使的与质量相关的职责,特别是药品质量体系的设计、有效实施、监测和维护。在遵守任何国家法规的前提下,这些职责可包括:
Other duties of Quality Control are summarised in Chapter 6. 2.9 The heads of Production, Quality Control and where relevant, Head of Quality Assurance or Head of Quality Unit, generally have some shared, or jointly exercised, responsibilities relating to quality including in particular the design, effective implementation, monitoring and maintenance of the Pharmaceutical Quality System. These may include, subject to any national regulations:
(i)书面规程和其他文件(包括修订)的批准;
(i) The authorisation of written procedures and other documents, including amendments;
(ii)生产环境的监测与控制;
(ii) The monitoring and control of the manufacturing environment;
(iii)工厂卫生;
(iii) Plant hygiene;
(iv)工艺验证;
(iv) Process validation;
(v)培训;
(v) Training;
(vi)物料供应商的批准与监测;
(vi) The approval and monitoring of suppliers of materials;
(vii)合同制造商及其他GMP相关外包活动
(vii) The approval and monitoring of contract manufacturers and providers of
提供商的批准与监测;
other GMP related outsourced activities;
(viii)物料和
(viii) The designation and monitoring of storage conditions for materials and
产品贮存条件的指定与监测;
products;
(ix)记录的保存;
(ix) The retention of records;
(x)对符合药品生产质量管理规范(GMP)要求的监测;
(x) The monitoring of compliance with the requirements of Good Manufacturing Practice;
(xi)进行检查、调查和取样,以监测可能影响产品质量的因素;
(xi) The inspection, investigation, and taking of samples, in order to monitor factors which may affect product quality;
(xii)参与
(xii) Participation in management reviews of process performance, product
工艺性能、产品质量和药品质量体系的管理评审,并倡导持续改进;
quality and of the Pharmaceutical Quality System and advocating continual improvement;
(xiii)确保建立及时有效的沟通与升级流程,
(xiii) Ensuring that a timely and effective communication and escalation process
将质量问题上报至适当的管理层级。 培训 2.10 制造商应为所有因职责需要进入生产区和贮存区或质量控制实验室的人员(包括技术、维护和清洁人员),以及其活动可能影响产品质量的其他人员提供培训。 2.11 除关于药品质量体系(PQS)和药品生产质量管理规范(GMP)理论与实践的基础培训外,新招聘人员还应接受与其所分配职责相适应的培训。还应提供持续培训,并定期评估其实效。培训计划应可获取,并根据情况由生产负责人或质量控制负责人批准。应保存培训记录。 2.12 在污染构成危害的区域(例如洁净区或处理高活性、有毒、感染性或致敏物料的区域)工作的人员,应接受专门培训。 2.13 参观者或未受培训的人员最好不应被带入生产和质量控制区。如果不可避免,应提前向其提供信息,特别是关于人员卫生和规定的防护服方面的信息。应对其密切监督。 2.14 培训期间应充分讨论药品质量体系(PQS)以及所有能够增进对其理解和实施的各项措施。 人员卫生 2.15 应建立详细的卫生计划,并适应厂内不同需求。卫生计划应包括与人员健康、卫生规范和着装相关的程序。每位因职责进入生产和控制区的人员都应以非常严格的方式理解并遵守这些程序。卫生计划应由管理层推动,并在培训期间广泛讨论。 2.16 所有人员在录用时均应接受体检。制造商必须负责制定规程,确保与产品质量可能相关的健康状况能够被(本块文本在此处截断)
exists to raise quality issues to the appropriate levels of management. TRAINING 2.10 The manufacturer should provide training for all the personnel whose duties take them into production and storage areas or into control laboratories (including the technical, maintenance and cleaning personnel), and for other personnel whose activities could affect the quality of the product. 2.11 Besides the basic training on the theory and practice of the Pharmaceutical Quality System and Good Manufacturing Practice, newly recruited personnel should receive training appropriate to the duties assigned to them. Continuing training should also be given, and its practical effectiveness should be periodically assessed. Training programmes should be available, approved by either the head of Production or the head of Quality Control, as appropriate. Training records should be kept. 2.12 Personnel working in areas where contamination is a hazard, e.g. clean areas or areas where highly active, toxic, infectious or sensitising materials are handled, should be given specific training. 2.13 Visitors or untrained personnel should, preferably, not be taken into the production and quality control areas. If this is unavoidable, they should be given information in advance, particularly about personal hygiene and the prescribed protective clothing. They should be closely supervised. 2.14 The Pharmaceutical Quality System and all the measures capable of improving its understanding and implementation should be fully discussed during the training sessions. PERSONNEL HYGIENE 2.15 Detailed hygiene programmes should be established and adapted to the different needs within the factory. They should include procedures relating to the health, hygiene practices and clothing of personnel. These procedures should be understood and followed in a very strict way by every person whose duties take him into the production and control areas. Hygiene programmes should be promoted by management and widely discussed during training sessions. 2.16 All personnel should receive medical examination upon recruitment. It must be the manufacturer’s responsibility that there are instructions ensuring that health conditions that can be of relevance to the quality of products come to the
制造商所知晓。首次体检之后,应根据工作和个人健康的需要,在必要时进行体检。 2.17 应采取步骤,在实际可行的范围内确保,患有传染病或身体暴露表面有开放性损伤的人员不参与药品生产。 2.18 每位进入生产区的人员均应穿戴与所进行操作相适应的防护服。 2.19 应禁止在生产区和贮存区进食、饮水、嚼食或吸烟,或存放食品、饮料、吸烟材料或个人药品。一般而言,在生产区内或产品可能受到不利影响的任何其他区域内,应禁止任何不卫生的行为。 2.20 应避免操作人员的手与暴露的产品以及任何与产品接触的设备部件直接接触。 2.21 应指导人员使用洗手设施。 2.22 特殊类别产品(例如无菌制剂)生产的任何特定要求,在附录中予以规定。 顾问 2.23 顾问应具备适当的教育、培训和经验,或其任何组合,以便就其所受聘咨询的课题提供建议。
manufacturer’s knowledge. After the first medical examination, examinations should be carried out when necessary for the work and personal health. 2.17 Steps should be taken to ensure as far as is practicable that no person affected by an infectious disease or having open lesions on the exposed surface of the body is engaged in the manufacture of medicinal products. 2.18 Every person entering the manufacturing areas should wear protective garments appropriate to the operations to be carried out. 2.19 Eating, drinking, chewing or smoking, or the storage of food, drink, smoking materials or personal medication in the production and storage areas should be prohibited. In general, any unhygienic practice within the manufacturing areas or in any other area where the product might be adversely affected should be forbidden. 2.20 Direct contact should be avoided between the operator’s hands and the exposed product as well as with any part of the equipment that comes into contact with the products. 2.21 Personnel should be instructed to use the hand-washing facilities. 2.22 Any specific requirements for the manufacture of special groups of products, for example sterile preparations, are covered in the annexes. CONSULTANTS 2.23 Consultants should have adequate education, training, and experience, or any combination thereof, to advise on the subject for which they are retained.
应保存记录,载明这些顾问的姓名、地址、资质以及所提供的服务类型。
Records should be maintained stating the name, address, qualifications, and type of service provided by these consultants.
第3章 厂房与设备
Chapter 3 Premises and equipment
原则
PRINCIPLE
厂房和设备必须位于适宜的地点,并经设计、建造、改造和维护以适合拟进行的操作。其布局和设计必须旨在将差错风险降至最低,并允许进行有效的清洁和维护,以避免交叉污染、灰尘或污物积聚,以及总体上对产品质量的任何不利影响。 厂房
Premises and equipment must be located, designed, constructed, adapted and maintained to suit the operations to be carried out. Their layout and design must aim to minimise the risk of errors and permit effective cleaning and maintenance in order to avoid cross-contamination, build-up of dust or dirt and, in general, any adverse effect on the quality of products. PREMISES
概述 3.1. 厂房所处的环境,在与保护生产的措施一并考虑时,应使造成物料或产品污染的风险降至最低。 3.2. 厂房应精心维护,确保修理和维护操作不对产品质量构成任何危害。厂房应根据详细的书面程序进行清洁,并在适用时进行消毒。 3.3. 照明、温度、湿度和通风应适宜,并且不得直接或间接对药品在生产与贮存期间或设备的准确运行产生不利影响。 3.4. 厂房应经过设计和配备,以最大程度防止昆虫或其他动物的进入。 3.5. 应采取措施防止未经授权人员的进入。生产区、贮存区和质量控制区不应被不在此工作的人员作为通道使用。
General 3.1. Premises should be situated in an environment which, when considered together with measures to protect the manufacture, presents minimal risk of causing contamination of materials or products. 3.2. Premises should be carefully maintained, ensuring that repair and maintenance operations do not present any hazard to the quality of products. They should be cleaned and, where applicable, disinfected according to detailed written procedures. 3.3. Lighting, temperature, humidity and ventilation should be appropriate and such that they do not adversely affect, directly or indirectly, either the medicinal products during their manufacture and storage, or the accurate functioning of equipment. 3.4. Premises should be designed and equipped so as to afford maximum protection against the entry of insects or other animals. 3.5. Steps should be taken in order to prevent the entry of unauthorised people. Production, storage and quality control areas should not be used as a right of way by personnel who do not work in them.
生产区 3.6 应通过生产设施的适当设计和操作,防止所有产品的交叉污染。防止交叉污染的措施应与风险相称。应使用质量风险管理原则来评估和控制风险。
Production Areas 3.6 Cross-contamination should be prevented for all products by appropriate design and operation of manufacturing facilities. The measures to prevent cross- contamination should be commensurate with the risks. Quality Risk Management principles should be used to assess and control the risks.
根据风险水平,可能有必要将厂房和设备专门用于某些药品的生产和/或包装操作,以控制其带来的风险。
Depending of the level of risk, it may be necessary to dedicate premises and equipment for manufacturing and/or packaging operations to control the risk presented by some medicinal products.
当药品因以下原因而构成风险时,生产需要专用设施:
Dedicated facilities are required for manufacturing when a medicinal product presents a risk because:
i. 该风险无法通过操作性和/或技术性措施充分控制, ii. 毒理学评价的科学数据不支持
i. the risk cannot be adequately controlled by operational and/ or technical measures, ii. scientific data from the toxicological evaluation does not support a
可控的风险(例如来自β-内酰胺类等高度致敏物料的致敏可能性),或 iii. 由毒理学评价得出的相关残留限度无法
controllable risk (e.g. allergenic potential from highly sensitising materials such as beta-lactams) or iii. relevant residue limits, derived from the toxicological evaluation, cannot be
通过经验证的分析方法满意地确定。
satisfactorily determined by a validated analytical method.
进一步指南可见第5章及附录2、3、4、5和6。 3.7. 厂房最好按如下方式布置:使生产能够在按操作顺序和所需洁净级别以逻辑顺序相连的区域中进行。 3.8. 工作和中间产品贮存空间的充足性应允许设备和物料有序、合理地放置,以将不同药品或其组分之间混淆的风险降至最低,避免交叉污染,并最大限度降低任何生产或控制步骤被遗漏或错误实施的风险。 3.9. 在起始物料和初级包装材料、中间产品或散装产品暴露于环境的情况下,内表面(墙、地面和天花板)应光滑、无裂缝和敞开接缝,且不脱落颗粒物,并应允许简便有效的清洁,且在必要时进行消毒。 3.10 管道、灯具、通风口和其他公用设施应经过设计和布置,以避免形成难以清洁的死角。为便于维护,应尽可能可从生产区外部接近。 3.11. 排水沟应有适当尺寸,并设有存水弯。应尽可能避免明沟,但如必要,应为浅沟以便于清洁和消毒。 3.12. 生产区应有效通风,并配备适宜的空气控制设施(包括温度,以及在必要时湿度和过滤),这些设施应既适合所处理的产品和区内所进行的操作,也适合外部环境。 3.13 起始物料的称量通常应在为此用途设计的单独称量室中进行。 3.14. 在产生粉尘的情况下(例如取样、称量、混合和加工过(本块文本在此处截断)
Further guidance can be found in Chapter 5 and in Annexes 2, 3, 4, 5 & 6. 3.7. Premises should preferably be laid out in such a way as to allow the production to take place in areas connected in a logical order corresponding to the sequence of the operations and to the requisite cleanliness levels. 3.8. The adequacy of the working and in-process storage space should permit the orderly and logical positioning of equipment and materials so as to minimise the risk of confusion between different medicinal products or their components, to avoid cross-contamination and to minimise the risk of omission or wrong application of any of the manufacturing or control steps. 3.9. Where starting and primary packaging materials, intermediate or bulk products are exposed to the environment, interior surfaces (walls, floors and ceilings) should be smooth, free from cracks and open joints, and should not shed particulate matter and should permit easy and effective cleaning and, if necessary, disinfection. 3.10 Pipework, light fittings, ventilation points and other services should be designed and sited to avoid the creation of recesses which are difficult to clean. As far as possible, for maintenance purposes, they should be accessible from outside the manufacturing areas. 3.11. Drains should be of adequate size, and have trapped gullies. Open channels should be avoided where possible, but if necessary, they should be shallow to facilitate cleaning and disinfection. 3.12. Production areas should be effectively ventilated, with air control facilities (including temperature and, where necessary, humidity and filtration) appropriate both to the products handled, to the operations undertaken within them and to the external environment. 3.13 Weighing of starting materials usually should be carried out in a separate weighing room designed for such use. 3.14. In cases where dust is generated (e.g. during sampling, weighing, mixing and processing operations, packaging of dry products), specific provisions should be taken to avoid cross-contamination and facilitate cleaning.
3.15. 药品包装用厂房应专门设计和布置,以避免混淆或交叉污染。 3.16 生产区应有良好照明,特别是在进行目视在线控制之处。 3.17. 过程控制可在生产区内进行,前提是其不对生产构成任何风险。
3.15. Premises for the packaging of medicinal products should be specifically designed and laid out so as to avoid mix-ups or cross-contamination. 3.16 Production areas should be well lit, particularly where visual on-line controls are carried out. 3.17. In-process controls may be carried out within the production area provided they do not carry any risk to production.
贮存区 3.18. 贮存区应有足够容量,以便有序存放各类物料和产品:起始物料和包装材料、中间体、散装产品和成品、待验产品、已放行产品、拒收产品、退回产品或召回产品。 3.19. 贮存区应经过设计或改造,以确保良好的贮存条件。特别是,应清洁、干燥,并将温度维持在可接受限度内。如需特殊贮存条件(例如温度、湿度),则应提供、检查并监测这些条件。 3.20 接收和发货站台应保护物料和产品免受天气影响。接收区应经过设计和配备,以便在必要时可在贮存前对来料的容器进行清洁。 3.21. 在以分区域存放确保待验状态的情况下,这些区域必须明确标识,且其进入仅限于经授权人员。任何替代实物待验的系统应提供同等的安保。 3.22. 通常应设有用于起始物料的单独取样区。如在贮存区内取样,应以防止污染或交叉污染的方式进行。 3.23. 应为拒收、召回或退回的物料或产品的贮存提供隔离区域。 3.24. 高活性物料或产品应贮存在安全可靠的区域内。 3.25. 印刷包装材料被视为对药品符合性至关重要,应特别注意这些物料的安全可靠贮存。
Storage Areas 3.18. Storage areas should be of sufficient capacity to allow orderly storage of the various categories of materials and products: starting and packaging materials, intermediate, bulk and finished products, products in quarantine, released, rejected, returned or recalled. 3.19. Storage areas should be designed or adapted to ensure good storage conditions. In particular, they should be clean and dry and maintained within acceptable temperature limits. Where special storage conditions are required (e.g. temperature, humidity) these should be provided, checked and monitored. 3.20 Receiving and dispatch bays should protect materials and products from the weather. Reception areas should be designed and equipped to allow containers of incoming materials to be cleaned where necessary before storage. 3.21. Where quarantine status is ensured by storage in separate areas, these areas must be clearly marked and their access restricted to authorised personnel. Any system replacing the physical quarantine should give equivalent security. 3.22. There should normally be a separate sampling area for starting materials. If sampling is performed in the storage area, it should be conducted in such a way as to prevent contamination or cross-contamination. 3.23. Segregated areas should be provided for the storage of rejected, recalled or returned materials or products. 3.24. Highly active materials or products should be stored in safe and secure areas. 3.25. Printed packaging materials are considered critical to the conformity of the medicinal product and special attention should be paid to the safe and secure storage of these materials.
质量控制区 3.26. 通常,质量控制实验室应与生产区分开。这对于生物制品、微生物制品和放射性同位素检验的实验室尤为重要,这些实验室之间也应相互分开。 3.27. 控制实验室应经过设计以适合其中所进行的操作。应给予充分空间以避免混淆和交叉污染。应有适当的适宜空间用于样品和记录的贮存。
Quality Control Areas 3.26. Normally, Quality Control laboratories should be separated from production areas. This is particularly important for laboratories for the control of biologicals, microbiologicals and radioisotopes, which should also be separated from each other. 3.27. Control laboratories should be designed to suit the operations to be carried out in them. Sufficient space should be given to avoid mix-ups and cross- contamination. There should be adequate suitable storage space for samples and records.
3.28. 可能需要单独的房间,以保护灵敏仪器免受振动、电气干扰、湿度等影响。 3.29. 处理特定物质(例如生物或放射性样品)的实验室需要有特殊要求。
3.28. Separate rooms may be necessary to protect sensitive instruments from vibration, electrical interference, humidity, etc. 3.29. Special requirements are needed in laboratories handling particular substances, such as biological or radioactive samples.
辅助区 3.30. 休息和茶歇室应与其他区域分开。 3.31. 更衣以及盥洗和如厕设施应易于接近,并适合使用人数。厕所不得直接与生产区或贮存区相通。 3.32. 维修车间应尽可能与生产区分开。凡零件和工具贮存在生产区内时,应保存在专供此用的房间或储物柜中。 3.33. 动物房应与其他区域良好隔离,设有单独的入口(动物通道)和空气处理设施。 设备 3.34. 生产设备应经过设计、放置和维护,以适合其预期用途。 3.35. 修理和维护操作不得对产品质量构成任何危害。 3.36. 生产设备应经过设计,以便能够容易而彻底地清洁。应按照详细书面程序清洁,并仅以清洁干燥的状态存放。 3.37. 清洗和清洁设备的选择与使用应不成为污染源。 3.38. 设备的安装方式应防止任何差错或污染风险。 3.39. 生产设备不得对产品构成任何危害。与产品接触的生产设备部件不得具有足以影响产品质量并因而构成危害的反应性、添加性或吸收性。 3.40. 应备有量程和精度适当的天平及测量设备,用于生产和控制操作。 3.41. 测量、称量、记录和控制的设备应按规定间隔采用适当方法进行校准和检查。应保存此类测试的适当记录。 3.42. 固定管道应清晰标识,以表明其内容物,并在适用时表明流向。
Ancillary Areas 3.30. Rest and refreshment rooms should be separate from other areas. 3.31. Facilities for changing clothes and for washing and toilet purposes should be easily accessible and appropriate for the number of users. Toilets should not directly communicate with production or storage areas. 3.32. Maintenance workshops should as far as possible be separated from production areas. Whenever parts and tools are stored in the production area, they should be kept in rooms or lockers reserved for that use. 3.33. Animal houses should be well isolated from other areas, with separate entrance (animal access) and air handling facilities. EQUIPMENT 3.34. Manufacturing equipment should be designed, located and maintained to suit its intended purpose. 3.35. Repair and maintenance operations should not present any hazard to the quality of the products. 3.36. Manufacturing equipment should be designed so that it can be easily and thoroughly cleaned. It should be cleaned according to detailed and written procedures and stored only in a clean and dry condition. 3.37. Washing and cleaning equipment should be chosen and used in order not to be a source of contamination. 3.38. Equipment should be installed in such a way as to prevent any risk of error or of contamination. 3.39. Production equipment should not present any hazard to products. Parts of production equipment that come into contact with the product must not be reactive, additive or absorptive to such an extent that it will affect the quality of the product and thus present any hazard. 3.40. Balances and measuring equipment of an appropriate range and precision should be available for production and control operations. 3.41. Measuring, weighing, recording and control equipment should be calibrated and checked at defined intervals by appropriate methods. Adequate records of such tests should be maintained. 3.42. Fixed pipework should be clearly labelled to indicate the contents and, where applicable, the direction of flow.
3.43. 蒸馏水、去离子水以及(在适当时)其他水管应根据书面程序进行消毒,该程序应详细说明微生物污染的行动限以及拟采取的措施。 3.44. 有缺陷的设备应尽可能撤离生产和质量控制区,或至少明确标识为缺陷设备。
3.43. Distilled, deionised and, where appropriate, other water pipes should be sanitised according to written procedures that detail the action limits for microbiological contamination and the measures to be taken. 3.44. Defective equipment should, if possible, be removed from production and quality control areas, or at least be clearly labelled as defective.
后续还会更新 Part I 其余章节(文件/生产/质控等)、Part II 原料药 GMP 及附录卷的中英双语完整版,点个关注 + 设为星标,别错过。
重要说明(务必读):
本系列为<药法知性研习社>
个人学习整理的非官方翻译,仅供行业交流与技术学习,不构成任何监管解释或官方意见,也不能替代贵司应执行的现行法律法规与官方文本。PIC/S 指南的版权归 PIC/S 所有,原文标注"禁止商业用途复制"(Reproduction prohibited for commercial purposes)。本号内容以"学习整理 + 解读增值"形式提供,如用于商业目的请先取得 PIC/S 书面授权。
来源:药法知行研习社 · mp.weixin.qq.com